دورية أكاديمية
أعرض في EDS

Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants.

التفاصيل البيبلوغرافية
العنوان: Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants.
المؤلفون: Matthew Cairns, Roly Gosling, Ilona Carneiro, Samwel Gesase, Jacklin F Mosha, Ramadhan Hashim, Harparkash Kaur, Martha Lemnge, Frank W Mosha, Brian Greenwood, Daniel Chandramohan
المصدر: PLoS ONE, Vol 5, Iss 3, p e9467 (2010)
بيانات النشر: Public Library of Science (PLoS), 2010.
سنة النشر: 2010
المجموعة: LCC:Medicine
LCC:Science
مصطلحات موضوعية: Medicine, Science
الوصف: Intermittent preventive treatment in infants (IPTi) is a new malaria control tool. However, it is uncertain whether IPTi works mainly through chemoprophylaxis or treatment of existing infections. Understanding the mechanism is essential for development of replacements for sulfadoxine-pyrimethamine (SP) where it is no longer effective. This study investigated how protection against malaria given by SP, chlorproguanil-dapsone (CD) and mefloquine (MQ), varied with time since administration of IPTi.A secondary analysis of data from a randomised, placebo-controlled trial in an area of high antifolate resistance in Tanzania was conducted. IPTi using SP, CD, MQ or placebo was given to 1280 infants at 2, 3 and 9 months of age. Poisson regression with random effects to adjust for potential clustering of malaria episodes within children was used to calculate incidence rate ratios for clinical malaria in defined time strata following IPTi. The short-acting antimalarial CD gave no protection against clinical malaria, whereas long-acting MQ gave two months of substantial protection (protective efficacy (PE) 73.1% (95% CI: 23.9, 90.5) and 73.3% (95% CI: 0, 92.9) in the first and second month respectively). SP gave some protection in the first month after treatment (PE 64.5% (95% CI: 10.6, 85.9)) although it did not reduce the incidence of malaria up to 12 months of age. There was no evidence of either long-term protection or increased risk of malaria for any of the regimens.Post-treatment chemoprophylaxis appears to be the main mechanism by which IPTi protects children against malaria. Long-acting antimalarials are therefore likely to be the most effective drugs for IPTi, but as monotherapies could be vulnerable to development of drug resistance. Due to concerns about tolerability, the mefloquine formulation used in this study is not suitable for IPTi. Further investigation of combinations of long-acting antimalarials for IPTi is needed.Clinicaltrials.gov NCT00158574.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1932-6203
Relation: http://europepmc.org/articles/PMC2830887?pdf=render; https://doaj.org/toc/1932-6203
DOI: 10.1371/journal.pone.0009467
URL الوصول: https://doaj.org/article/d9b96ecf78214928a4924ea6efd17891
رقم الأكسشن: edsdoj.9b96ecf78214928a4924ea6efd17891
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:19326203
DOI:10.1371/journal.pone.0009467